Table 6.
Predictor | Sample A (N = 649) | Sample B (N = 544) | ||||||
---|---|---|---|---|---|---|---|---|
b | 95% CI | SE | p | b | 95% CI | SE | p | |
Change in ill-being during pandemic onset (T1 to T2)a | ||||||||
Intercept | 34.72 | [32.66, 36.77] | 1.05 | < .001 | 33.99 | [31.62, 36.36] | 1.21 | < .001 |
Time | 1.29 | [0.85, 1.73] | 0.23 | < .001 | 1.37 | [1.01, 1.74] | 0.19 | < .001 |
Partner | −4.52 | [−7.58, −1.45] | 1.56 | .004 | –5.02 | [−8.16, −1.87] | 1.60 | .002 |
Time × Partner | 1.03 | [0.37, 1.68] | 0.33 | .002 | 0.18 | [−0.30, 0.67] | 0.25 | .455 |
Linear change in ill-being after pandemic onset (T2 through T7) | ||||||||
Intercept | 34.23 | [32.11, 36.35] | 1.08 | < .001 | 33.03 | [30.56, 35.50] | 1.26 | < .001 |
Time | −0.25 | [−0.33, −0.16] | 0.05 | < .001 | –0.33 | [−0.43, −0.23] | 0.05 | < .001 |
Partner | −5.13 | [−8.28, −1.99] | 1.60 | .001 | –3.95 | [−7.22, −0.67] | 1.67 | .018 |
Time × Partner | −0.12 | [−0.25, 0.01] | 0.07 | .068 | 0.03 | [−0.10, 0.16] | 0.07 | .617 |
Quadratic change in ill-being after pandemic onset (T2 through T7) | ||||||||
Intercept | 33.24 | [31.04, 35.45] | 1.12 | < .001 | 31.78 | [29.17, 34.38] | 1.33 | < .001 |
Time | −0.23 | [−0.32, −0.15] | 0.04 | < .001 | –0.31 | [−0.41, 0.21] | 0.05 | < .001 |
Time2 | 0.02 | [0.01, 0.03] | 0.01 | < .001 | 0.03 | [0.01, 0.04] | 0.01 | < .001 |
Partner | −5.52 | [−8.78, −2.26] | 1.66 | < .001 | –4.07 | [−7.50, −0.63] | 1.75 | .021 |
Time × Partner | −0.11 | [−0.24, 0.01] | 0.06 | .081 | 0.03 | [−0.10, 0.15] | 0.06 | .690 |
Time2 × Partner | 0.01 | [−0.01, 0.03] | 0.01 | .220 | 0.00 | [−0.02, 0.02] | 0.01 | .781 |
Average ill-being after pandemic onset (T2 through T7) | ||||||||
Intercept | 34.66 | [32.54, 36.77] | 1.08 | < .001 | 33.63 | [31.15, 36.11] | 1.26 | < .001 |
Partner | −5.12 | [−8.27, −1.98] | 1.60 | .002 | –4.21 | [−7.51, −0.93] | 1.67 | .012 |
Note: CI = confidence interval; T1 = February 2020; T2 = March 2020; T7 = September 2020.
For these analyses, sample sizes were 647 for Sample A and 543 for Sample B.